Zymeworks appoints Suzanne Monahan senior vice president and general manager of Theravance Biopharma. October 19, 2026 Suzanne Monahan Zymeworks Inc. (Nasdaq: ZYME), a Vancouver-based biotechnology company, has appointed Suzanne Monahan senior vice president, commercial and general manager of Theravance Biopharma, effective October 19, 2026. Monahan will report directly to Kenneth Galbraith, chairman and chief executive officer of Zymeworks, and oversee commercial strategy and execution for YUPELRI (revefenacin), a respiratory medicine added to the company's portfolio through its recent acquisition of Theravance Biopharma. The appointment comes as Zymeworks expands its commercial pharmaceutical operations while continuing to develop a pipeline of novel biotherapeutics and manage a portfolio of licensed healthcare assets. YUPELRI is the first and only once-daily, nebulized long-acting muscarinic antagonist approved in the United States for the maintenance treatment of chronic obstructive pulmonary disease (COPD). In her new position, Monahan will be responsible for advancing the product's commercial strategy, supporting market access initiatives and working with the existing YUPELRI team to expand its reach among healthcare providers and eligible patients. Monahan brings more than 20 years of commercial leadership experience across the pharmaceutical and medical device industries, with a background spanning sales, marketing, commercial operations, distribution, market access and strategic partnerships. Galbraith said her experience launching and expanding pharmaceutical products will support Zymeworks' commercial objectives following the Theravance acquisition. "Suzanne is a proven commercial leader who has launched, scaled and grown products across hospital, specialty, and respiratory markets, and who knows how to build strong partnerships that deliver results," Galbraith said. "Her track record of driving sustained growth and her deep experience in market access and strategic collaborations make her ideally suited to lead our commercial efforts for YUPELRI." Most recently, Monahan served as senior vice president at Pacira BioSciences, where she held commercial leadership responsibilities across multiple sales organizations and a strategic partnerships group. During her tenure, she also participated in joint steering and commercial committees responsible for overseeing partnered pharmaceutical brands. Before joining Pacira, Monahan spent more than five years at Shionogi Inc., most recently serving as vice president of sales. At Shionogi, she led the launch of a hospital-based intravenous antibiotic targeting gram-negative bacterial infections and oversaw commercial operations that achieved sustained double-digit annual growth. Earlier in her career, Monahan served as vice president of a business unit at Circassia Pharmaceuticals, where she managed a respiratory diagnostic device business with full profit-and-loss responsibility. Her responsibilities at Circassia also included supporting a partnership involving the relaunch of a long-acting muscarinic antagonist product in the COPD market. That experience provides a direct connection to her new responsibilities involving YUPELRI, which is also used in the maintenance treatment of COPD. Monahan began her pharmaceutical career at Sanofi-Aventis and subsequently spent nine years at Salix Pharmaceuticals in positions of increasing responsibility. At Salix, her leadership roles included national sales director for institutional, federal and specialty accounts. She earned a Bachelor of Arts in psychology with a minor in marketing from Quinnipiac University. Monahan said she looks forward to building on the commercial foundation established for YUPELRI. "I am thrilled to join Zymeworks at such an important time for the Company and for YUPELRI," Monahan said. "YUPELRI is a differentiated medicine that makes a real difference for people living with COPD, and I am excited to work with the talented YUPELRI team to build on its momentum and to help more patients and providers benefit from it." The appointment reflects Zymeworks' strategy of combining commercial and near-commercial pharmaceutical assets with its internal research and development capabilities. The company is building a diversified portfolio intended to generate recurring cash flows while supporting the development of treatments for difficult-to-treat diseases. The addition of YUPELRI through the Theravance Biopharma acquisition expands Zymeworks' presence in the respiratory therapeutics market. The company also has interests in Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines. Another portfolio asset is pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks' proprietary antibody engineering technologies. Beyond these assets, Zymeworks is advancing research programs involving antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. Its proprietary Azymetric platform supports the development of engineered antibody-based therapeutics. The company's broader business model combines internal drug development, licensing arrangements, commercial partnerships and the acquisition of healthcare assets. As general manager of Theravance Biopharma, Monahan will help lead the commercial activities associated with YUPELRI within that structure. Her responsibilities will include coordinating commercial execution and leveraging her experience in respiratory medicine, pharmaceutical sales and strategic partnerships to support the product's continued development in the market. The appointment adds an experienced pharmaceutical commercial executive to Zymeworks' leadership team as the company integrates Theravance Biopharma and expands its commercial operations alongside its biotechnology research programs.

The South Jordan Journal is the local newspaper covering news and events in the City of South Jordan, Utah. The South Jordan Journal provides one of the best advertising channels to the residents of the City of South Jordan.

Pacira partners with Molteni for Exparel commercialisation. The companies expect the first commercial sale under the partnership to occur in 2027. Pacira BioSciences has entered into an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialise Exparel across the EU and the UK. Exparel (bupivacaine liposome injectable suspension), is a long-acting local analgesic used for postsurgical pain management. Under the agreement, Pacira will obtain an undisclosed upfront payment, alongside a supply price and royalties generated from future commercial sales across the licensed territories. Pacira will be responsible for manufacturing the therapy. Molteni Farmaceutici will manage regulatory procedures, market access, and commercialisation efforts in the designated markets. Molteni Farmaceutici plans a phased commercial rollout of the analgesic, starting in Austria, Germany, Italy, and Poland, while also seeking regulatory approval in Switzerland. The companies expect the first commercial sale under the partnership to occur in 2027. Locust Walk served as the exclusive financial advisor to Pacira for the transaction. Pacira BioSciences CEO Frank Lee said: "Pharmaceutical Technology is excited to announce another strategic partnership that advances its 5x30 growth strategy and reinforces its commitment to expanding patient access to best-practice opioid-sparing postsurgical pain management. "With Molteni Farmaceutici's longstanding leadership in pain management and extensive distribution network across Europe, they are ideally positioned to unlock EXPAREL's full potential in key European markets." Molteni Farmaceutici focuses on specialty healthcare, operating in the fields of hospital-based treatments, oncology supportive care, and pain management. Alongside Exparel, Pacira's commercial portfolio includes Zilretta (triamcinolone acetonide extended-release injectable suspension), an intra-articular extended-release injection indicated for managing osteoarthritis knee pain. The company is also developing a pipeline of clinical-stage candidates for musculoskeletal pain and related conditions. Its investigational product, PCRX-201 (enekinragene inzadenovec), is a locally administered gene therapy currently undergoing Phase II clinical development for knee osteoarthritis. In November 2025, AmacaThera entered into an exclusive worldwide licensing agreement with Pacira BioSciences for up to $230m for AMT-143, an investigational long-acting non-opioid anaesthetic. Give your business an edge with its leading industry insights.